PubRank

Giuseppe Castello

Author PubWeight™ 54.90‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 2005 2.28
2 Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 2005 1.88
3 Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol 2004 1.83
4 Differential role of CD133 and CXCR4 in renal cell carcinoma. Cell Cycle 2010 1.73
5 Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma. BJU Int 2013 1.58
6 Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol 2010 1.45
7 Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin Cancer Res 2006 1.37
8 Human immunodeficiency virus per se exerts atherogenic effects. Atherosclerosis 2008 1.17
9 Human melanoma metastases express functional CXCR4. Clin Cancer Res 2006 1.15
10 Mitochondrial dysfunction in some oxidative stress-related genetic diseases: Ataxia-Telangiectasia, Down Syndrome, Fanconi Anaemia and Werner Syndrome. Biogerontology 2010 1.07
11 Prognostic value of serum VEGF in melanoma patients: a pilot study. Anticancer Res 2005 1.06
12 Serum cytokine levels in patients with hepatocellular carcinoma. Eur Cytokine Netw 2010 1.02
13 Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells. Cancer Immunol Immunother 2004 0.99
14 Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. J Clin Oncol 2003 0.97
15 Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy. Eur J Cancer 2006 0.96
16 Evidence of publication bias in clinical trials of biotherapies for solid tumors. Cancer 2005 0.94
17 Multiple evidence for an early age pro-oxidant state in Down Syndrome patients. Biogerontology 2006 0.94
18 Structural and functional studies of the human selenium binding protein-1 and its involvement in hepatocellular carcinoma. Biochim Biophys Acta 2011 0.94
19 Oxidative stress in Fanconi anaemia: from cells and molecules towards prospects in clinical management. Biol Chem 2012 0.94
20 Oxidative stress and mitochondrial dysfunction in Down syndrome. Adv Exp Med Biol 2012 0.93
21 Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. J Transl Med 2010 0.93
22 Human Cytokinome: a new challenge for systems biology. Bioinformation 2010 0.93
23 Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases. PLoS One 2013 0.92
24 Serum cytokine levels as putative prognostic markers in the progression of chronic HCV hepatitis to cirrhosis. Eur Cytokine Netw 2010 0.91
25 CXC chemokine receptor 4 is expressed in uveal malignant melanoma and correlates with the epithelioid-mixed cell type. Cancer Immunol Immunother 2007 0.91
26 Cytokinome profile of patients with type 2 diabetes and/or chronic hepatitis C infection. PLoS One 2012 0.91
27 Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome. J Transl Med 2012 0.90
28 In vivo prooxidant state in Werner syndrome (WS): results from three WS patients and two WS heterozygotes. Free Radic Res 2005 0.90
29 Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis. J Gastroenterol Hepatol 2007 0.88
30 From clinical description, to in vitro and animal studies, and backward to patients: oxidative stress and mitochondrial dysfunction in Fanconi anemia. Free Radic Biol Med 2013 0.87
31 A possible predictive marker of progression for hepatocellular carcinoma. Oncol Lett 2011 0.87
32 Is serum Interleukin-17 associated with early atherosclerosis in obese patients? J Transl Med 2014 0.86
33 Adjuvant treatment of malignant melanoma: where are we? Crit Rev Oncol Hematol 2005 0.85
34 CytokineDB: a database collecting biological information. Bioinformation 2009 0.85
35 Soluble interleukin-2 receptor in stage I-III melanoma. Cytokine 2006 0.85
36 Effects of lipoic acid, caffeic acid and a synthesized lipoyl-caffeic conjugate on human hepatoma cell lines. Molecules 2011 0.83
37 Sjøgren's syndrome-associated oxidative stress and mitochondrial dysfunction: prospects for chemoprevention trials. Free Radic Res 2012 0.83
38 Bone marrow cell transcripts from Fanconi anaemia patients reveal in vivo alterations in mitochondrial, redox and DNA repair pathways. Eur J Haematol 2013 0.82
39 Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders. J Transl Med 2010 0.82
40 Ascorbic acid: its role in immune system and chronic inflammation diseases. Mini Rev Med Chem 2014 0.82
41 A point mutation (G574A) in the chemokine receptor CXCR4 detected in human cancer cells enhances migration. Cell Cycle 2009 0.81
42 Evaluation of selenite effects on selenoproteins and cytokinome in human hepatoma cell lines. Molecules 2013 0.81
43 Lauroside B, a megastigmane glycoside from Laurus nobilis (bay laurel) leaves, induces apoptosis in human melanoma cell lines by inhibiting NF-κB activation. J Nat Prod 2010 0.80
44 Impaired diastolic function in naïve untreated human immunodeficiency virus infected patients. World J Cardiol 2010 0.80
45 A holistic approach to study the effects of natural antioxidants on inflammation and liver cancer. Cancer Treat Res 2014 0.79
46 Mutation analysis of candidate genes in melanoma-prone families: evidence of different pathogenetic mechanisms at chromosome 9P21. Melanoma Res 2003 0.79
47 Common structural interactions between the receptors CXCR3, CXCR4 and CXCR7 complexed with their natural ligands, CXCL11 and CXCL12, by a modeling approach. Cytokine 2013 0.79
48 CytReD: A database collecting human cytokinome information. Bioinformation 2011 0.78
49 Assessment of genetic instability in melanocytic skin lesions through microsatellite analysis of benign naevi, dysplastic naevi, and primary melanomas and their metastases. Melanoma Res 2003 0.78
50 The N-terminal region of CXCL11 as structural template for CXCR3 molecular recognition: synthesis, conformational analysis, and binding studies. Chem Biol Drug Des 2012 0.78
51 Cancer biomarker profiling in patients with chronic hepatitis C virus, liver cirrhosis and hepatocellular carcinoma. Oncol Rep 2013 0.78
52 Peptides targeting chemokine receptor CXCR4: structural behavior and biological binding studies. J Pept Sci 2014 0.77
53 Dissimilar cytokine patterns in different human liver and colon cancer cell lines. Cytokine 2013 0.77
54 Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma. BMC Cancer 2006 0.76
55 Early diagnosis of malignant melanoma: Proposal of a working formulation for the management of cutaneous pigmented lesions from the Melanoma Cooperative Group. Int J Oncol 2003 0.76
56 Complex mixture-associated hormesis and toxicity: the case of leather tanning industry. Dose Response 2008 0.75
57 CD4(+)CD45RA(+)CXCR4 (+) lymphocytes are inversely associated with progression in stages I-III melanoma patients. Cancer Immunol Immunother 2009 0.75
58 The gene expression profiling of hepatocellular carcinoma by a network analysis approach shows a dominance of intrinsically disordered proteins (IDPs) between hub nodes. Mol Biosyst 2015 0.75
59 Prospective clinical trials of biotherapies in solid tumors: a 5-year survey. Cancer Immunol Immunother 2005 0.75